Oruka Therapeutics Cash Flow Statement
NASDAQ: ORKAHealth CareBiotechnology: In Vitro & In Vivo Diagnostic SubstancesUSD
82.11+4.83 (+6.25%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Oruka Therapeutics free cash flow
In fiscal 2025, Oruka Therapeutics generated -$88.2 million of operating cash flow and spent $209,000 on capital expenditures. That left free cash flow of -$88.4 million.
Summary generated from market data by MetaCap's automated system. Methodology
Oruka Therapeutics cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 | FY 20152015-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -105.43M | -5.34M | -9.93M | -19.32M | -9.74M | -5.48M | -7.93M | -18.49M | -16.44M | -11.45M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 83.00K | 15.00K | 20.00K | 16.00K | 8.00K | 18.00K | 22.00K | 27.00K | 24.00K | 19.00K |
| Stock-Based Compensation | 24.24M | 686.00K | 556.00K | 497.00K | 43.00K | 151.00K | 273.00K | 458.00K | 576.00K | 599.00K |
| Change in Working Capital | -3.97M | 28.00K | -783.00K | -411.00K | 1.10M | 188.00K | -392.00K | -583.00K | 841.00K | -431.00K |
| Operating Cash Flow | -88.21M | -5.01M | -10.91M | -18.76M | -7.72M | -4.80M | -8.24M | -17.47M | -14.99M | -10.53M |
| Capital Expenditures | -209.00K | 0 | -2.00K | -43.00K | -19.00K | -4.00K | -4.00K | -3.00K | -12.00K | -11.00K |
| Investing Cash Flow | -96.75M | 0 | -2.00K | -43.00K | -19.00K | -4.00K | 3.05M | 12.93M | -16.41M | -11.00K |
| Financing Cash Flow | 170.31M | 0 | 0 | 23.09M | 48.45M | 6.56M | 3.10M | 5.85M | — | 33.99M |
| Net Change in Cash | -14.64M | -5.01M | -10.91M | 4.29M | 40.71M | 1.75M | -2.09M | 1.30M | — | — |
| Free Cash Flow | -88.42M | -5.01M | -10.91M | -18.80M | -7.74M | -4.80M | -8.25M | -17.48M | -15.00M | -10.54M |
This table shows 10 annual periods of Oruka Therapeutics's cash flow statement, from FY 2025 back to FY 2015, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow ORKA's reporting calendar. What is a cash flow statement?